LU600091B1 - Method for removing small extracellular vesicles in foetal bovine serum based on secondary differential centrifugation method - Google Patents

Method for removing small extracellular vesicles in foetal bovine serum based on secondary differential centrifugation method

Info

Publication number
LU600091B1
LU600091B1 LU600091A LU600091A LU600091B1 LU 600091 B1 LU600091 B1 LU 600091B1 LU 600091 A LU600091 A LU 600091A LU 600091 A LU600091 A LU 600091A LU 600091 B1 LU600091 B1 LU 600091B1
Authority
LU
Luxembourg
Prior art keywords
bovine serum
foetal bovine
extracellular vesicles
small extracellular
centrifuge
Prior art date
Application number
LU600091A
Other languages
German (de)
Inventor
Kuandong Li
Kun Deng
Original Assignee
The Third Affiliated Hospital Of Cqmu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Third Affiliated Hospital Of Cqmu filed Critical The Third Affiliated Hospital Of Cqmu
Priority to LU600091A priority Critical patent/LU600091B1/en
Application granted granted Critical
Publication of LU600091B1 publication Critical patent/LU600091B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention discloses a method for removing small extracellular vesicles in foetal bovine serum based on a secondary differential centrifugation method, wherein a large amount of nutrient factors and macromolecular factors necessary for cell growth are extracted by high-speed centrifugation, and then mixed with a phosphate buffer saline solution in an appropriate proportion for secondary ultra-high-speed centrifugation to further purify the foetal bovine serum and remove residual small extracellular vesicles. The present invention can retain the nutrients required for cell growth to the greatest extent, and the cultured suspension cells are viable after multiple passages; the present invention aims to meet the demand for high-quality foetal bovine serum without small extracellular vesicles in scientific research and industrial production.

Description

DESCRIPTION LU600091
METHOD FOR REMOVING SMALL EXTRACELLULAR VESICLES IN FOETAL
BOVINE SERUM BASED ON SECONDARY DIFFERENTIAL CENTRIFUGATION
METHOD
TECHNICAL FIELD
The invention relates to the field of biotechnology, and in particular to a method for removing small extracellular vesicles in foetal bovine serum based on a secondary differential centrifugation method.
BACKGROUND
Foetal bovine serum (FBS) is collected from the foetal blood of young embryos in the process of growth and differentiation, it is rich in nutrients and growth factors and is often used in laboratory scientific research on cell culture. Small extracellular vesicles are a general term for tiny vesicles less than 200 nanometres in size that are actively secreted by cells and contain proteins, DNA, and metabolites. Studies have shown that small extracellular vesicles complete information exchange through cell-to-cell transmission mechanisms, and are also involved in the occurrence and development of a variety of diseases, and have the potential to serve as a diagnostic marker for cancer.
FBS contains a large number of bovine-derived small extracellular vesicles, which will be absorbed by growing cells during the cell culture process, causing changes in cell viability and migration. Most importantly, they are similar in morphology and content to the small extracellular vesicles produced by cells, making them difficult to separate, which hinders downstream analysis.
At present, there are few studies on the removal of small extracellular vesicles in foetal bovine serum in China. The present invention removes small extracellular vesicles in foetal bovine serum based on a differential ultracentrifugation device.
Compared with the commercialized removal of small extracellular vesicles in foetal bovine serum, it can remove small extracellular vesicles in foetal bovine serum while retaining the nutrients required for cell growth to the greatest extent, meet the subsequent cell proliferation and growth needs, and is friendly to downstream analysis.
SUMMARY
The objective of the present invention is to provide a method for removing small LU800091 extracellular vesicles in foetal bovine serum based on a secondary differential centrifugation method, aiming to improve the purity of foetal bovine serum and meet the demand for high-quality exosome-free foetal bovine serum in scientific research and industrial production.
In order to solve the above technical problems, the present invention adopts the following technical schemes: the method for removing small extracellular vesicles in foetal bovine serum based on the secondary differential centrifugation method of the present invention includes the following steps: ultracentrifuging the foetal bovine serum firstly using a high-speed centrifuge, extracting nutrient factors and macromolecular factors necessary for cell growth, and removing part of small extracellular vesicles, mixing a phosphate buffered saline solution PBS and the foetal bovine serum again and performing secondary centrifugation using an ultra-high-speed centrifuge, and removing residual small extracellular vesicles and obtaining foetal bovine serum without small extracellular vesicles.
The method for removing small extracellular vesicles in foetal bovine serum based on the secondary differential centrifugation method has the following specific steps: step 1: shaking an ordinary foetal bovine serum evenly and dispensing 72 ml into six 15 ml centrifuge tubes in a fume hood, with 12 ml in each tube; step 2: using a high-speed centrifuge to perform a balanced centrifugation operation on the centrifuge tubes of the ordinary foetal bovine serum at a relative centrifugal force of 26,000xg for 19 hours; step 3: after the high-speed centrifuge stops working, slowly taking out the six centrifuge tubes, and placing them on the centrifuge rack, using a pipette to gently draw the foetal bovine serum from the centrifuge tubes from top to bottom, and discarding the first 10 ml, collecting 2 ml of the foetal bovine serum from the bottom of each centrifuge tube and placing it in six new Beckman ultra-high-speed centrifuge tubes; step 4: mixing 10 mL of phosphate buffered saline solution in six new Beckman ultra-high speed centrifugal tubes containing 2mL of the foetal bovine serum, and performing a balanced centrifugation at a relative centrifugal force of 100,000xg for 2 hours;
step 5: after the centrifugation, marking the small extracellular vesicles at the LU600091 bottom of the centrifuge tubes, and carefully collecting a mixture of foetal bovine serum and phosphate buffered saline solution to prevent inhalation of the precipitate, and the collected is the foetal bovine serum with small extracellular vesicles removed.
As one of the preferred technical schemes, the specific steps are as follows: step 1, mixing a commercial foetal bovine serum evenly and dispensing 12 mL into six identical 15 mL centrifuge tubes; step 2, centrifuging the six centrifuge tubes containing foetal bovine serum at a relative centrifugal force of 26,000xg for 19 hours; step 3, after the centrifugation, collecting 2 mL of the foetal bovine serum from the bottom of the tubes and placing in a new centrifuge tube, mixing with 10 mL of
PBS solution and centrifuging for 2 hours at a relative centrifugal force of 100,000xg; step 4, after the centrifugation, collecting a mixture of the foetal bovine serum and the phosphate buffered saline solution in a new centrifuge tube, and the collected is the foetal bovine serum with small extracellular vesicles removed.
As one of the further preferred technical schemes,
In step 1, mixing can be done by turning upside down 15 times.
In step 2, the centrifuge tube must be sterile, non-toxic and non-polluting, and the centrifuge must be strictly balanced.
In step 3, the PBS used is from Thermo Fisher Life Sciences Mall, with item number 10010023, and needs to be filtered with a 0.22-micron filter before use; the centrifuge model used is Beckman Optima XPN-100, which needs to be weighed and balanced with a precision balance, with an error of less than 0.01g.
In step 4, after the centrifugation, a feather-like precipitate can be seen at the bottom of the tubes, which is the small extracellular vesicle precipitate, which needs to be marked with a marker pen, and the collection operation needs to be gentle and the centrifuge tubes cannot be shaken.
Compared with the prior art, the beneficial technical effects of the present invention are as follows. 1. The method for removing small extracellular vesicles from foetal bovine serum based on secondary differential centrifugation can retain the nutrients and growth factors in foetal bovine serum to the greatest extent compared with the imported foetal bovine serum with small extracellular vesicles removed based on ultrafiltration, meeting the needs of subsequent cell experiments, and cell growth is LU600091 not affected; the basic principle of ultrafiltration is to use ultrafiltration membranes with different relative molecular weight cut-off (MWCO) to selectively separate samples, and during the ultrafiltration process, solvents and small molecules are filtered to the other side of the membrane, while relatively large molecules are retained on the ultrafiltration membrane, thereby achieving the purpose of separation. 2. Compared with the traditional method of single 100,000xg ultracentrifugation for 19 hours, the use time of large centrifugal equipment is reduced and the safety is increased. 3. The present invention can achieve the same removal effect as the commercial reagent based on ultrafiltration method to remove small extracellular vesicles of foetal bovine serum, and no saucer-shaped small extracellular vesicles are observed under the transmission electron microscope (TEM).
TEM is a microscope that transmits an accelerated and concentrated electron beam to a very thin sample, and the electrons collide with the atoms in the sample and change direction, thus producing a three-dimensional angle scattering. The internal structure of the material can be directly observed at the atomic scale, and electron diffraction analysis of the crystal structure of the material can be performed at the same time to obtain information on the material's phase and crystal structure.
The resolution of the transmission electron microscope of small extracellular vesicles is 0.1 to 0.2 nm, and it can be observed whether there is a typical structure in the sample, usually in the shape of a concave saucer.
BRIEF DESCRIPTION OF THE FIGURES
The present invention is further described below in conjunction with the accompanying drawings.
Fig. 1 is a schematic diagram of the process of the present invention;
Fig. 2 is a schematic diagram of the components of foetal bovine serum through ultrafiltration and secondary differential ultracentrifugation;
Fig. 3 is a protein blot analysis of small extracellular vesicle marker proteins
TSG101, CD63 and CD9:
Fig. 4 is a scanning electron microscopic observation of small extracellular vesicles (C);
Fig. 5 is a microscopic image of human multiple myeloma cells U266 growing LU600091 in complete culture medium supplemented with different serum configurations at different time periods;
Fig. 6 is a concentration comparison diagram based on a method for obtaining small extracellular vesicles from different samples by traditional ultracentrifugation (100,000xg, for 2 hours).
DESCRIPTION OF THE INVENTION
Embodiment 1
As shown in Fig. 1, the separation method for removing small extracellular vesicles in foetal bovine serum based on a secondary ultracentrifugation has the following specific steps: (1) sterilizing a 15 ml centrifuge tube, thawing the commercial Gibco foetal bovine serum and dividing it into six 15 ml centrifuge tubes, with 12 ml in each centrifuge tube, and the whole process is performed in a clean bench to reduce the possibility of being contaminated by bacteria; (2) balancing and centrifuging the six centrifuge tubes containing Gibco foetal bovine serum at 26,000 x g for 19 hours; (3) after the centrifugation, slowly taking out the centrifuge tubes and placing in a pre-prepared centrifuge tube rack, and taking 2 ml of foetal bovine serum at the bottom of the tube and placing in six new Beckman ultracentrifuge tubes. Be careful not to absorb the precipitate on the wall of the tube, as the precipitate is small extracellular vesicles: (4) adding 10 ml of PBS to each Beckman ultracentrifuge tube for balancing, and then centrifuging at 100,000 x g for 2 hours using a Beckman ultracentrifuge
Optima XPN-100; and (5) after the centrifugation, removing the Beckman ultracentrifuge tube and discarding the small extracellular vesicles precipitate at the bottom of the tube, and the remaining portion is the foetal bovine serum without small extracellular vesicles.
The applicant designed a comparative experiment (small extracellular vesicle- depleted serum (UC-dFBS) obtained by secondary differential ultrafiltration of foetal bovine serum, small extracellular vesicle-depleted sample (UF-dFBS) obtained by ultrafiltration, small extracellular vesicle-depleted sample (UC1-dFBS) obtained by first centrifugation of ordinary foetal bovine serum, ordinary foetal bovine serum (FBS) and commercial small extracellular vesicle-depleted serum (OriCell-dFBS))
and conducted a Coomassie brilliant blue staining experiment; and the specific LU600091 method is as follows: Coomassie brilliant blue, its core principle lies in the non- covalent bond binding with protein and the colour change characteristics, and in protein staining applications, Coomassie brilliant blue forms a stable complex through electrostatic binding and van der Waals force with the amino and carboxyl groups in the protein, and this complex can stabilize the negative charge carried by the dye, thereby producing a distinct blue colour on the membrane or gel, which is convenient for observation and analysis.
Fig. 2 is a schematic diagram and nomenclature of the components of foetal bovine serum obtained by ultrafiltration and secondary differential ultracentrifugation, as well as the results of total protein staining with Coomassie
Brilliant Blue. (A) Samples obtained by ultrafiltration of foetal bovine serum, and the upper layer sample is the retentate, which is divided into three equal parts and named as ultrafiltration foetal bovine serum retentate 1 (UF-FBS-remain1), ultrafiltration foetal bovine serum retentate 2 (UF-FBS-remain2), and ultrafiltration foetal bovine serum retentate 3 (UF-FBS-remain3); the lower layer sample is the ultrafiltration depleted extracellular vesicle sample (UF-dFBS), which is also divided into three equal parts and named as ultrafiltration depleted extracellular vesicle serum 1 (UF-dFBS-1), ultrafiltration depleted extracellular vesicle serum 2 (UF-dFBS-2), and ultrafiltration depleted extracellular vesicle serum 3 (UF-dFBS-3). (B) Coomassie brilliant blue staining results of the retentate obtained by ultrafiltration of foetal bovine serum and ultrafiltration serum depleted of small extracellular vesicles.
Fig. 2 (C) is the extracellular vesicle-depleted serum (UC-dFBS) obtained by secondary differential ultracentrifugation of foetal bovine serum, and UC-sEv is the extracellular vesicle precipitate at the bottom of the foetal bovine serum centrifuge tube obtained by secondary differential ultracentrifugation; Fig. 2(D) shows that the extracellular vesicle-depleted serum obtained by secondary differential ultracentrifugation of foetal bovine serum has a higher protein content than the extracellular vesicle-depleted sample (UF-dFBS) obtained by ultrafiltration; Fig. (E) shows that the extracellular vesicle precipitate at the bottom of the foetal bovine serum centrifuge tube obtained by secondary differential ultracentrifugation has a lower protein content; Fig. (F) shows that the extracellular vesicle-depleted serum
(UC-dFBS) obtained by secondary differential ultracentrifugation of foetal bovine LU800091 serum and the extracellular vesicle-depleted sample (UF-dFBS) obtained by ultrafiltration have lower protein contents than the extracellular vesicle-depleted sample (UC1-dFBS) obtained by the first centrifugation of ordinary foetal bovine serum, ordinary foetal bovine serum (FBS) and commercial extracellular vesicle- depleted serum (OriCell-dFBS).
The principle of Western Blotting to detect small extracellular vesicle marker proteins TSG101, CD63 and CDS is briefly described as follows: electrophoretic separation: separating the proteins according to their molecular weight by SDS-PAGE electrophoresis; membrane transfer. transfering the separated proteins from the gel to the membrane, maintaining their positional relationship and molecular weight; antibody binding: using specific antibodies to bind to the target protein (TSG101, CD63, CDS), and the antibodies are usually labeled with detection substances. signal detection: detecting the binding signal of the antibody and protein by staining, fluorescence or chemiluminescence to determine the presence and concentration of the target protein.
Fig. 3 shows Western blot analysis of small extracellular vesicle marker proteins
TSG101, CD63 and CDS. Western blot analysis of small extracellular vesicle marker proteins TSG101, CD63 and CDS in different samples is performed by traditional ultracentrifugation to obtain small extracellular vesicles (100,000 xg for 2 hours): ordinary foetal bovine serum (FBS), ultrafiltered small extracellular vesicle-depleted serum (UF-dFBS), commercial small extracellular vesicle-depleted serum (OriCell- dFBS) and ultra-depleted small extracellular vesicle serum (UC-dFBS).
As shown in Fig. 3, the results show that the content of small extracellular vesicle marker proteins TSG101, CD63 and CD9 bands in ultra-depleted small extracellular vesicle serum (UC-dFBS) is very small, indicating that ultra-depleted small extracellular vesicle serum (UC-dFBS) does not contain small extracellular vesicles, while foetal bovine serum FBS used as a positive control contains a large number of small extracellular vesicles.
Fig. 4 is a scanning electron microscopic observation of small extracellular vesicles (sEVs), and (A) is the scanning electron microscopic result of small extracellular vesicles (sEVs) in ordinary foetal bovine serum (FBS, and (B) is the scanning electron microscopic result of small extracellular vesicles (sEVs) based on LU600091 ultracentrifugation-depleted small extracellular vesicle serum (UF-dFBS).
As shown in Fig. 4, in order to visually see whether there are small extracellular vesicles in the ultra-depleted small extracellular vesicle serum (UC-dFBS), a scanning electron microscopy observation experiment is performed, and the scanning electron microscope of foetal bovine serum (FBS) as a positive control shows many saucer-shaped small extracellular vesicles, while the ultra-depleted small extracellular vesicle serum (UC-dFBS) does not contain small extracellular vesicles.
As shown in Fig. 5, in order to determine whether ultra-depleted extracellular vesicle serum (UC-dFBS) can meet the normal growth and proliferation of cells, human multiple myeloma cells U266 are observed under an inverted microscope at different time periods. The experimental results show that U266 cells could still proliferate normally after 4 days, and the cell density is higher than that of ultra- depleted extracellular vesicle serum (UF-dFBS) and commercial extracellular vesicle-depleted serum (OriCell-dFBS).
As shown in Fig. 5, in order to determine the concentration of residual small cell extracellular vesicles in UC-dFBS for NTA detection, Zetaview-PMX120-Z uses the properties of light scattering and Brownian motion to accurately measure the particle size distribution of the sample in the particle size range of 1 to 1000 nm. The device can provide detailed information about the particle size of the sample by capturing and analysing these physical phenomena. NTA results show that the extracellular vesicle-depleted sample (UF-dFBS) obtained by ultrafiltration has the lowest extracellular vesicle concentration, and the extracellular vesicle-depleted serum (UC-dFBS) obtained by secondary differential ultracentrifugation of foetal bovine serum and commercial extracellular vesicle-depleted serum (OriCell-dFBS) have lower extracellular vesicle content than that of the extracellular vesicle-depleted sample (UC1-dFBS) obtained by the first centrifugation of ordinary foetal bovine serum and ordinary foetal bovine serum (FBS).
Comprehensive analysis of the above results shows that the small extracellular vesicle-depleted serum (UC-dFBS) obtained by secondary differential ultracentrifugation of foetal bovine serum retains most of the nutrients required for cell growth and meets the needs of cell proliferation and growth, and the small extracellular vesicle removal effect is better than that of commercial small LU600091 extracellular vesicle-depleted serum (OriCell-dFBS).
The above embodiments are only for describing the preferred embodiments of the invention and are not intended to limit the scope of the invention. Without departing from the scope or spirit of the invention, various modifications and improvements made to the technical schemes of the invention by people of ordinary skill in the art should fall within the protection scope determined by the claims of the invention.

Claims (4)

1. A method for removing small extracellular vesicles in foetal bovine serum based on the secondary differential centrifugation method, characterised in that the method comprises the following steps: ultracentrifuging the foetal bovine serum firstly using a high-speed centrifuge, extracting nutrient factors and macromolecular factors necessary for cell growth, and removing part of small extracellular vesicles, mixing a phosphate buffered saline solution PBS and the foetal bovine serum again and performing secondary centrifugation using an ultra-high-speed centrifuge, and removing residual small extracellular vesicles and obtaining foetal bovine serum without small extracellular vesicles.
2. The method for removing small extracellular vesicles in foetal bovine serum based on the secondary differential centrifugation method according to claim 1, characterised in that the specific steps are as follows: step 1: shaking an ordinary foetal bovine serum evenly and dispensing 72 ml into six 15 ml centrifuge tubes in a fume hood, with 12 ml in each tube; step 2: using a high-speed centrifuge to perform a balanced centrifugation operation on the centrifuge tubes of the ordinary foetal bovine serum at a relative centrifugal force of 26,000xg for 19 hours; step 3: after the high-speed centrifuge stops working, slowly taking out the six centrifuge tubes, and placing them on the centrifuge rack, using a pipette to gently draw the foetal bovine serum from the centrifuge tubes from top to bottom, and discarding the first 10 ml, collecting 2 ml of the foetal bovine serum from the bottom of each centrifuge tube and placing it in six new Beckman ultra-high-speed centrifuge tubes; step 4: mixing 10 mL of phosphate buffered saline solution in six new Beckman ultra-high speed centrifugal tubes containing 2mL of the foetal bovine serum, and performing a balanced centrifugation at a relative centrifugal force of 100,000xg for 2 hours; and step 5: after the centrifugation, marking the small extracellular vesicles at the bottom of the centrifuge tubes, and carefully collecting a mixture of foetal bovine serum and phosphate buffered saline solution to prevent inhalation of the precipitate, and the collected is the foetal bovine serum with small extracellular LU800091 vesicles removed.
3. The method for removing small extracellular vesicles in foetal bovine serum based on the secondary differential centrifugation method according to claim 1, characterised in that in step 3, the ultracentrifuge is a Beckman ultracentrifuge with a model of Optima XPN-100.
4. The method for removing small extracellular vesicles in foetal bovine serum based on the secondary differential centrifugation method according to claim 1, characterised in that in step 3, 2 mL of foetal bovine serum is collected from the bottom of the tubes and placed in a centrifuge tube, and careful operation is required to prevent the small extracellular vesicles precipitated on the tube wall from being sucked in, and it is recommended to use a 100 pl pipette for fine operation.
LU600091A 2025-01-21 2025-01-21 Method for removing small extracellular vesicles in foetal bovine serum based on secondary differential centrifugation method LU600091B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LU600091A LU600091B1 (en) 2025-01-21 2025-01-21 Method for removing small extracellular vesicles in foetal bovine serum based on secondary differential centrifugation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU600091A LU600091B1 (en) 2025-01-21 2025-01-21 Method for removing small extracellular vesicles in foetal bovine serum based on secondary differential centrifugation method

Publications (1)

Publication Number Publication Date
LU600091B1 true LU600091B1 (en) 2025-07-21

Family

ID=96474986

Family Applications (1)

Application Number Title Priority Date Filing Date
LU600091A LU600091B1 (en) 2025-01-21 2025-01-21 Method for removing small extracellular vesicles in foetal bovine serum based on secondary differential centrifugation method

Country Status (1)

Country Link
LU (1) LU600091B1 (en)

Similar Documents

Publication Publication Date Title
Wolff et al. Separation of Hela cells by colloidal silica density gradient centrifugation: I. Separation and partial synchrony of mitotic cells
Smith et al. Methods for collection, handling, and analysis of sea urchin coelomocytes
CN107858324B (en) Method for adsorbing and separating extracellular vesicles including exosomes secreted by cells to culture medium based on anion exchange resin
CN112251406B (en) Exosome sorting method in NK cell activation stage
CN114591905B (en) Method for preparing apoptotic vesicles from human erythrocytes and application of apoptotic vesicles
WO2020173466A1 (en) Method for preparing mature red blood cells in vitro using peripheral blood
CN102154201A (en) Human marrow, cord blood or peripheral blood stem cells treating kit and stem cells separating method
JP2020531852A (en) Quality control substances used in urine sediment analyzers using a microscope and how to use them
Ravelo et al. Magnetic-activated cell sorting for the fast and efficient separation of human and rodent Schwann cells from mixed cell populations
CN113416693A (en) Preparation method of mesenchymal stem cell exosome
CN117778309A (en) Isolation and purification methods of animal stem cell exosomes and their applications
CN115537389A (en) Preparation method of umbilical cord mesenchymal stem cell source exosome with inflammation regulation function
CN113046317A (en) Method for extracting platelet-rich plasma based on preparation of umbilical cord blood hematopoietic stem cells
Crawford Purification of polyoma virus
CN107254438A (en) The separation method of PMNC
JP6272296B2 (en) Method and apparatus for homogeneous distribution of suspended cellular components
JP2023123105A (en) Method for purifying extracellular vesicles
EP0813442B1 (en) Method for enriching rare cell population
Hall The initiation and maintenance of plant cell suspension cultures
CN121852473A (en) Automatic preparation process and application of CAR-immune cells
CN115838686A (en) Method for purifying human mesenchymal stem cell-derived small extracellular vesicles on large scale
CN105018411A (en) Cell sorting method
CN118460459A (en) Large-scale stem cell exosome extraction method
CN115948330A (en) Serum-free medium suitable for proliferation of bone marrow mesenchymal stem cells and its application
Boyle et al. [17] Preparation and processing of small samples of human material

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20250721